E-Posters-Effect of an Antimuscarinic on Fecal Incontinence in Women with Double Incontinence

Effect of an Antimuscarinic on Fecal Incontinence in Women with Double Incontinence - Lindsay Martin Kissane, MD

Pdf Summary

This study aimed to evaluate the effect of antimuscarinic therapy on fecal incontinence (FI) symptom severity in women with double incontinence. The study was a single-arm, prospective open-label cohort study. Women aged 18 and above with bothersome urgency urinary incontinence (UUI) and FI were included in the study. Baseline questionnaires assessing FI symptom severity, fecal incontinence quality of life (FIQL), and overactive bladder (OAB) symptoms were completed. Participants were then treated with darifenacin 15mg daily for 8 weeks. Questionnaires were completed again, along with a patient global impression of improvement (PGI-I) and a repeat bowel diary. <br /><br />A total of 32 women were enrolled in the study, with 28 subjects completing it. The mean age of participants was 66.5, and the majority were post-menopausal. At baseline, the mean St. Marks (Vaizey) score was 17.8, indicating moderate FI symptom severity. Following 8 weeks of antimuscarinic therapy, there was a significant improvement in FI symptom severity, with a mean St. Marks (Vaizey) score of 11.0. The frequency of FI episodes per week also decreased significantly from a median of 7 to 1. <br /><br />The study found that 67.9% of participants met the minimal important difference (MID) for improvement in FI symptom severity. Additionally, 64.3% reported that their FI symptoms were at least "much better" on the PGI-I. All four subscales of the FIQL showed significant improvement. The most common adverse events reported were dry mouth and constipation.<br /><br />Overall, the findings suggest that antimuscarinic therapy, specifically darifenacin, is a safe and effective treatment option for women with double incontinence. The study provides important evidence to guide healthcare providers in treating this patient population, and it supports considering antimuscarinic medication early in the treatment algorithm for double incontinence.

Keywords

antimuscarinic therapy

fecal incontinence

double incontinence

symptom severity

women

prospective open-label cohort study

darifenacin

St. Marks (Vaizey) score

minimal important difference

overactive bladder